A5102833793- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Virology and Viral Diseases
- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- Genomics and Phylogenetic Studies
- Zoonotic diseases and public health
- vaccines and immunoinformatics approaches
- Microbial infections and disease research
- COVID-19 epidemiological studies
- Infective Endocarditis Diagnosis and Management
- COVID-19 Clinical Research Studies
- Escherichia coli research studies
- SARS-CoV-2 detection and testing
- Vaccine Coverage and Hesitancy
- Reproductive tract infections research
- Viral gastroenteritis research and epidemiology
- Vector-Borne Animal Diseases
- Viral Infections and Vectors
- Antibiotic Resistance in Bacteria
- Venous Thromboembolism Diagnosis and Management
- Diagnosis and Treatment of Venous Diseases
- Streptococcal Infections and Treatments
Coalition for Epidemic Preparedness Innovations
2019-2024
Norwegian Institute of Public Health
2012-2021
Institut de Recherche Vaccinale
2020
Background. The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1–29-year-olds Burkina Faso 2010. It is not known whether MenAfriVac has an impact on NmA carriage.
ABSTRACT The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a study determine baseline rate and distribution before introduction in 1- 29-year old population Burkina Faso, group chosen for first vaccine. multiple cross-sectional was conducted one urban two rural districts Faso 2009. Every 3 months, oropharyngeal samples were collected from...
Background The serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination campaigns December 2010 Burkina Faso, Mali and Niger. In the coming years, will be extended to other African countries at risk of epidemics. To document molecular characteristics disease-causing strains circulating meningitis belt Africa before vaccine introduction, World Health Organization Collaborating Centers on Meningococci Europe United States established a common strain...
The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a significant effect of vaccination on NmA carriage for one year following mass 2010. new study was performed October-November 2012, two years after MenAfriVac vaccination. Oropharyngeal samples were collected and analysed presence N. (Nm) from representative...
Meningococcal colonization is a prerequisite for transmission and disease, but the bacterium only very infrequently causes disease while asymptomatic carriage common. Carriage highly dynamic, showing great variety across time space within populations, also individuals. The understanding of genetic changes in meningococcus during carriage, when bacteria resides its natural niche, important not state, dynamics entire meningococcal population. Paired isolates, obtained from 50 carriers about 2...
During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.The new effectiveness evaluation framework was established by World Health Organization partners. Meningitis case-based surveillance strengthened PsA-TT first-introducer several studies were conducted estimate vaccination coverage measure impact on carriage disease...
Neisseria meningitidis colonizes humans and transmits mainly by asymptomatic carriage. We sought to determine the prevalence epidemiology of meningococcal carriage in Ethiopia prior introduction MenAfriVac, a serogroup A conjugate vaccine. cross-sectional study was conducted Arba Minch, southern Ethiopia. total 7479 oropharyngeal samples were collected from 1 29 year old volunteers, between March October, 2014. The swabs cultured for N. lactamica isolates confirmed characterized their...
The bacterium Neisseria meningitidis of serogroups A and W-135 has in the recent decade caused most cases meningococcal meningitis African belt, there is currently no efficient affordable vaccine available demonstrated to protect against both these serogroups. Previously, deoxycholate-extracted outer membrane vesicle (OMV) vaccines serogroup B meningococci have been shown be safe induce protection humans clonal outbreaks. strains isolated from belt epidemics demonstrate strikingly limited...
Neisseria lactamica is a true commensal bacterium occupying the same ecological niche as pathogenic meningitidis, which responsible for outbreaks and large epidemics, especially in sub-Saharan Africa. To better understand epidemiology of N. Africa its relationship to we studied carriage 1- 29-year-old people living three districts Burkina Faso from 2009 2011. was detected 18.2% 45,847 oropharyngeal samples. Carriage prevalence highest among 2-year-olds (40.1%) decreased with age. Overall...
The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of the 1-29-year-olds Burkina Faso 2010. aim this study to genetically characterize meningococcal isolates circulating before and up 13 months after MenAfriVac vaccination. total 1,659 carriage were collected a repeated cross-sectional three districts 2010 2011, Forty-two invasive through national surveillance same period. All 817 characterized by serogroup,...
Meningococcal conjugate vaccines induce serum antibodies crucial for protection against invasive disease. Salivary are believed to be important hindering meningococcal acquisition and/or clearance of established carriage. In this study, we measured salivary IgA and IgG induced by vaccination with a monovalent serogroup A vaccine or tetravalent A, C, W Y vaccine, in comparison antibody levels serum. Saliva samples from Ethiopian volunteers (1-29 years) collected before eight times on weekly...
In the first 2 years after a nationwide mass vaccination campaign of 1-29-year-olds with meningococcal serogroup A conjugate vaccine (MenAfriVac) in Burkina Faso, carriage and disease due to Neisseria meningitidis were nearly eliminated. We aimed assess long-term effect MenAfriVac on herd immunity.We did four cross-sectional studies people aged 9 months 36 two districts Faso between May 2, 2016, Nov 6, 2017. Demographic information oropharyngeal swabs collected. Meningococcal isolates...